Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.315 USD | +0.22% | -5.12% | -45.01% |
05:46pm | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
Apr. 25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.01% | 517M | |
+1.84% | 42.59B | |
+8.43% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+9.19% | 24.81B | |
-23.95% | 18.17B | |
+29.11% | 12.05B | |
-3.17% | 11.7B | |
+7.27% | 11.1B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac Starts Phase 1 Trial of COVID-19 Vaccine Candidate for Omicron Variant